Keyword search (4,164 papers available)

"cancer survivors" Keyword-tagged Publications:

Title Authors PubMed ID
1 Symptom burden, healthcare utilization, and risky behaviors in survivors of the childhood cancer survivor study (CCSS): an observation cohort study Webster R; Srivastava DK; Xie L; Darji H; Liu W; McGrady ME; Brinkman TM; Alberts NM; Ness KK; Fuemmeler B; Kunin-Batson AS; Huang IC; Armstrong GT; Howell RM; Green DM; Yasui Y; Krull KR; 41340862
PSYCHOLOGY
2 Prevalence and characteristics of neuropathic pain in adolescent survivors of childhood cancer Mesaroli G; Olaizola S; Nair A; Nishat F; Pizzo A; Nathan PC; Alberts NM; Stinson JN; 40999274
PSYCHOLOGY
3 Intolerance of uncertainty, psychological symptoms, and pain in long-term childhood cancer survivors: a report from the Childhood Cancer Survivor Study Alberts NM; Stratton KL; Leisenring WM; Pizzo A; Lamoureux É; Alschuler K; Flynn J; Krull KR; Jibb LA; Nathan PC; Olgin JE; Stinson JN; Armstrong GT; 40699439
PSYCHOLOGY
4 Cannabidiol and multi-modal exercise for chemotherapy-induced peripheral neuropathy in cancer survivors Vigano M; Kubal S; Habib S; Samarani S; Kasvis P; Koudieh N; Kilgour R; Farzin H; Ahmad A; Vigano A; Costiniuk CT; 40464985
HKAP
5 "We don't do any of these things because we are a death-denying culture": Sociocultural perspectives of Black and Latinx cancer caregivers Nwakasi C; Esiaka D; Nweke C; Chidebe RCW; Villamar W; de Medeiros K; 39327878
SOCANTH
6 Cancer Survivors' Evolving Perceptions of a New Supportive Virtual Program Robb A; Brown TL; Durand A; Loiselle CG; 36354724
PSYCHOLOGY
7 An investigation into socio-demographic-, health-, and cancer-related factors associated with cortisol and C-reactive protein levels in breast cancer survivors: a longitudinal study. Lambert M, Sabiston CM, Wrosch C, Brunet J 32488733
PSYCHOLOGY

 

Title:Cannabidiol and multi-modal exercise for chemotherapy-induced peripheral neuropathy in cancer survivors
Authors:Vigano MKubal SHabib SSamarani SKasvis PKoudieh NKilgour RFarzin HAhmad AVigano ACostiniuk CT
Link:https://pubmed.ncbi.nlm.nih.gov/40464985/
DOI:10.1007/s00520-025-09553-z
Publication:Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Keywords:Cancer survivorshipCannabidiolCannabinoidsChemotherapy-induced peripheral neuropathyMulti-modal exercise
PMID:40464985 Category: Date Added:2025-06-04
Dept Affiliation: HKAP
1 Division of Experimental Medicine, Faculty of Medicine and Health Sciences, Graduate Program in Clinical and Translational Research, McGill University, Montreal, Quebec, Canada.
2 Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
3 Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
4 McGill Nutrition and Performance Laboratory, Research Institute-McGill University Health Centre, Montreal, QC, Canada.
5 Department of Health, Kinesiology and Applied Physiology, Concordia University, Montreal, QC, Canada.
6 School of Human Nutrition, McGill University, Macdonald Campus, Sainte-Anne-de-Bellevue, QC, Canada.
7 Division of Palliative Care, Jewish General Hospital, Montreal, Canada.
8 Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
9 Department of Microbiology,

Description:

Purpose: This study explored the effectiveness of cannabidiol (CBD) alone and in combination with multi-modal exercise (MME) to improve signs and symptoms of chemotherapy-induced peripheral neuropathy (CIPN), quality of life (QoL), and functional capacity in cancer survivors.

Methods: Cancer survivors (n = 27) with CIPN were enrolled in a 4-month interventional open-label study. Participants underwent two consecutive 2-month interventions: CBD (up to 300 mg/day) and CBD combined with MME. They were assessed using the painDETECT questionnaire for CIPN-related neuropathic pain and the Functional Assessment of Cancer Treatment/Gynecological Oncology-Neurotoxicity-13 (FACT-GOG-Ntx-13) questionnaire for CIPN neurotoxic symptoms (Ntx), perceived physical function (PPF) and overall QoL. Their functional status was examined through gait speed and timed up and go for mobility, the 9-hole peg test for manual dexterity, a hand-held hydraulic dynamometer for hand grip strength, and five repetitions sit-to-stand for dynamic balance, upper/lower extremity and overall strength.

Results: Positive effect sizes were measured by Cohen's d or Cohen's r with 95% confidence intervals (CI) from mean scores, and were d 0.62, CI 0.03-1.20 for Ntx; d 0.62, CI 0.09-1.26 for PPF; and r 0.401, CI 0.13-0.61 for hand grip strength after 2 months of CBD alone. After adding MME to CBD for another 2 months, the effect sizes were d 0.526, CI -0.15-1.19 for painDETECT; d 0.862, CI 0.67-1.55 for CIPN neurotoxic symptoms; d 1.03, CI 0.30-1.74 for perceived physical function; r 0.447, CI 0.15-0.67 for overall QoL; r 0.339, CI 0.03-0.59 for gait speed; and r 0.389, CI 0.08-0.63 for manual dexterity.

Conclusions: The study provides a proof of concept for the therapeutic effect of CBD alone and in combination with MME to improve symptoms' burden, QoL and functional impairments related to CIPN in patients who are cured from cancer. Future randomized studies are needed to confirm the causal effects of CBD and exercise on CIPN, and to replicate our findings.





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University